US EditionTelix’s Illuccix® PSMA-PET Imaging Agent Approved in the Czech Republic
Summary by Telix
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Telix’s Illuccix® PSMA-PET Imaging Agent Approved in the Czech Republic
Telix’s Illuccix® PSMA-PET Imaging Agent Approved in the Czech Republic New approval provides hospitals and clinics in the Czech Republic with access to a proven PSMA-PET imaging agent Melbourne (Australia) | 5 May 2025 Telix today announces that its prostate cancer PET[1] imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in the Czech Republic by the SÚKL[2] for the…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
